seminar

QB3 Webinar: Sonja Schrepfer, Sana Biotechnology. "The Future of Stem Cell Therapy: Hypoimmune Cell Products"

Induced pluripotent stem cells (iPSCs) hold great potential as therapies to repair damaged tissue or replace cell types missing due to genetic defects. However, even iPSCs derived from a patient can mutate in culture, causing immune rejection when they are re-transplanted. Being able to control immune rejection is key to using iPSCs as theraputics. The end goal, for safety and efficiency, is a gene-engineered, hypoimmunogenic, universal cell product. In this talk, Sonja Schrepfer of Sana Biotechnologies will describe how she and Sana are working to ensure that transplanted iPSCs survive both T cell and innate immune surveillance.

Where & When

Zoom Webinar
1:00 to 2:00 PM PT, Wednesday, September 15, 2021

About the Speaker

Headshot_Sonja_Schrepfer.jpg

Sonja Schrepfer, MD, PhD, is Head of Hypoimmune Platform at Sana Biotechnology, an Adjunct Professor at University of California, San Francisco in the Department of Surgery, and Founder of the Transplant and Stem Cell Immunobiology (TSI) lab at Stanford University.

Sonja received her MD and PhD from the Universities Wuerzburg and Hamburg where she was awarded the Heisenberg Professorship for her work to understand the immune barrier in stem cell biology for regenerative medicine. Sonja and her team subsequently decreased the immunogenic potential of stem cells to generate hypo-immunogenic tissues and organs, work that was funded by the California Institute for Regenerative Medicine and National Institutes of Health among others.

QB3 Webinar: John York, Impossible Foods. "The Science of Saving the Planet"

As Chief Science Officer at Impossible Foods, Dr. John York, PhD, leads a fast-growing R&D team expected to double in size in 2021. Before joining the company in January, York served as the Chair of the Department of Biochemistry and a Professor of Biochemistry at Vanderbilt University from 2012 to 2020, where his laboratory paved the way for discoveries in protein structure and function, cell signaling and molecular genetics. He joined Impossible Foods because, as he says, “the opportunity to use biochemistry to save the planet is a spectacular motivation.” Now, Dr. York is finding a new lab and headquarters for the company's R&D operations in the Bay Area, and he’s leading the company's world-class scientists as they develop the next generation of sustainable ingredients to solve our ecological crisis. Join this talk to learn about his research and how he is approaching his new role.

The event was rescheduled for July 15 due to a conflict on Dr. York’s calendar.

Where & When

Zoom Webinar
1:00 to 2:00 PM, Thursday, July 15, 2021

About the Speaker

York_John.jpg

Dr. John D. York joined Impossible Foods in January 2021 as Chief Science Officer. John oversees the company’s research and development and product innovation functions. His work focuses on building Impossible’s technology platform, expanding basic research capabilities, accelerating next-generation products, and recruiting the world’s best scientists to join the Impossible Foods team.

From 2012 to 2020, John was the Chair of the Department of Biochemistry and Professor of Biochemistry at Vanderbilt University. There, John’s laboratory paved the way for discoveries in protein structure and function, cell signaling, and molecular genetics, and furthered our understanding of the pathophysiology of disease. Under his leadership as Department Head, the Department of Biochemistry became 2019’s top NIH-funded department in the nation and nearly doubled the number of trainees.

Before joining Vanderbilt, John was an investigator for the Howard Hughes Medical Institute and Professor in Pharmacology and Biochemistry at Duke University,

Throughout his career, John trained over 50 scientists in his laboratory and over 200 graduate students, post doctoral fellows, undergraduates and high-school students through thesis, departmental and community activities.

A Midwest native, John received his BS in Biochemistry from the University of Iowa and his Ph.D. in Molecular Cell Biology and Biochemistry from Washington University in Saint Louis. Outside of the lab, he enjoys spending time with his wife and two incredibly wonderful daughters, off-piste skiing, tennis, woodworking, building outdoor pizza ovens, cooking (more importantly, eating!), traveling and reading the news from a variety of intellectually rigorous sources.v

QB3 Webinar: David Baker, University of Washington. "Designing Proteins from Scratch for 21st Century Challenges"

Billions of years of evolution have proteins that perform incredibly specialized functions. But evolution must take a continuous path. What if, given all we now know about how structure relates to function, we could shortcut evolution and custom-design proteins for our own aims? We can. In this talk, David Baker of the University of Washington's Institute for Protein Design will describe how his group designs and fabricates enzymes, motor proteins, biologics delivery vehicles, and other sophisticated macromolecules from first principles.

Where & When

Zoom Webinar
1:00 to 2:00 PM, Wednesday, July 7, 2021

About the Speaker

david baker uw.png

David Baker is the director of the Institute for Protein Design, a Howard Hughes Medical Institute Investigator, the Henrietta and Aubrey Davis Endowed Professor in Biochemistry, and an adjunct professor of genome sciences, bioengineering, chemical engineering, computer science, and physics at the University of Washington. His research group is focused on the design of macromolecular structures and functions.

He received his Ph.D. in biochemistry with Randy Schekman at the University of California, Berkeley, and did postdoctoral work in biophysics with David Agard at UCSF. 

Dr. Baker has received awards from the National Science Foundation, the Beckman Foundation, and the Packard Foundation. He is the recipient of the Breakthrough Prize in Life Sciences, Irving Sigal and Hans Neurath awards from the Protein Society, the Overton Prize from the ISCB, the Feynman Prize from the Foresight Institute, the AAAS Newcomb Cleveland Prize, the Sackler prize in biophysics, and the Centenary Award from the Biochemical society. Sixty-five of his mentees have gone on to independent faculty positions, he has published over 500 research papers, been granted over 100 patents, and co-founded 11 companies.

Dr. Baker is a member of the National Academy of Sciences and the American Academy of Arts and Sciences. He is also a project leader with The Audacious Project.

QB3 Webinar: Slone Partners Panel. How to Incorporate Diversity, Equity, and Inclusion into Your Startup Culture

Early-stage entrepreneurs have their hands full as they seek funding, leadership talent, and a startup strategy that will allow them to gain momentum from the get-go. Having an effective diversity, equity, and inclusion (DEI) plan in place from day one gives employees the space and security they need to thrive. A recent survey found that when they work in an inclusive culture, 83% of millennials report being more actively engaged in their work. 

In this webinar, Slone Partners President Tara Kochis-Stach will lead a conversation where panelists will share insights and best practices, and outline pragmatic steps early-stage companies can take to incorporate DEI into workplace culture.

In this informative webinar, we will discuss:

  • How to conceptualize diversity, equity, and inclusion in a startup setting

  • How to develop an effective, actionable, and sustainable DEI strategy from day one

  • How to facilitate candid conversations and healthy, open dialogue

  • How to prioritize three things you can do right now to further your DEI objectives

Where & When

Zoom Webinar
1:00 to 2:00 PM, Thursday, April 8, 2021

Resources

Links provided by the panelists.

About the Speakers

Moderator: Tara Kochis-Stach, President, Slone Partners

Tara-Kochis-Stach.jpg

Tara joined Slone Partners in 2004, bringing to the company over a decade of healthcare experience. Her successful sales career with industry leaders such as VERSYSS, American Medical Laboratories, and Quest Diagnostics covered a wide variety of healthcare segments, including information technology, medical records, and the diagnostic and laboratory testing industry.

Prior to healthcare, Tara recruited executive and management talent in the banking and finance sector. Tara’s executive abilities and business acumen have been instrumental in building Slone Partners into the successful and growing company it is today. Tara drives business development strategies, creating strong partnerships with new clients and strengthening relationships with existing clients. She is a tremendous resource for clients and prospects alike.

Through her partnership with Springboard Enterprises, she is an advisor to Blumio, a startup company focused on building sensors and systems to improve health and wellness, as well as a frequent panelist and speaker at industry conferences and a participant in select industry committees; activities that provide continuing opportunities to expand Slone Partners’ knowledge and expertise in the industries we serve.

Tara graduated cum laude from Boston College, receiving a Bachelor of Science with a concentration in Human Resources Management.

Panelists

QB3 Webinar: Angèle Maki. "Emerging Technology at Lilly Gateway Labs"

In recent years a growing number of industry-leading pharma companies have opened their own incubators to access early innovation in life science hubs such as the Bay Area. In late 2019 Eli Lilly opened Lilly Gateway Labs (LGL) in South San Francisco. As we know at QB3, startup founders are hungry for lab space and keen on learning from other innovators. During this webinar, we’ll learn about Lilly’s approach with LGL, what technologies and/or assets the company is looking for, and what other factors matter. Join us on February 16 for an overview from Angèle Maki, Vice President of Emerging Technology & Innovation at Eli Lilly and Company.

Where & When

Zoom Webinar
1:00 to 2:00 PM, Tuesday, February 16, 2021

About the Speaker

angele+maki.jpg

Dr. Angèle Maki is a business development executive with sixteen years of deal-making experience spanning small biotech and big pharma. She is currently a Vice President of Emerging Technology & Innovation at Eli Lilly and Company where she leads search & evaluation efforts in the Bay Area for Lilly Research Labs. At Lilly she also plays key roles with Lilly Gateway Labs, Lilly’s new incubator-like facility in SSF, and with Lilly New Ventures, Lilly’s corporate VC group.

Prior to Lilly, Angèle held business development roles with increasing responsibility starting at Medarex followed by BMS (which acquired Medarex), Genentech, 23andMe, and Merck & Co. During her career, she has successfully negotiated numerous in- and out-licensing transactions, from early-stage research technologies to clinical-stage assets.

Angèle has a Ph.D. in biological chemistry from Stanford University and completed postdoctoral work in molecular biology at The Scripps Research Institute in La Jolla. She completed her B.Sc. in chemistry at the University of Winnipeg in Canada.

QB3 Webinar: Nick Shenkin, Federal Bureau of Investigation. "IP Piracy in Life Science"

Nick and his task force created the Delta protocol: the FBI’s advice on how to protect your startup and its intellectual property. Download it

For many life science startups, IP is the most crucial factor that determines whether they succeed or fail. An innovative concept and freedom to operate are essential to winning investment.

But hostile foreign and domestic actors want to steal ideas and data from scientists and entrepreneurs. They target the most vulnerable: academics and early-stage companies.

Are you one of these targets? Do you want to know what threats you face and what you can do to protect yourself? Join us on Wednesday, January 27 to hear from FBI Special Agent Nicholas Shenkin, Director of the Strategic Technology Task Force for the FBI’s San Francisco Field Division.

Where & When

Zoom Webinar
1:00 to 2:00 PM, Wednesday, January 27, 2021

Event held in partnership with UCSF IT Security.

About the Speaker

nick shenkin 2020.jpg

Nicholas Shenkin is an FBI Special Agent and the Director of the Strategic Technology Task Force for the FBI’s San Francisco Field Division. Nicholas is a Counterintelligence specialist and leads a staff of Special Agents and Intelligence Analysts responsible for hardening the target of 400+ Cleared Defense Contractors, Silicon Valley, Lawrence Livermore National Lab, Lawrence Berkeley National Lab, and all businesses and academic institutions in the San Francisco Field Division. In 1996, prior to his engagement with the Bureau, Nicholas started a high-security hosting and data analysis company. Nicholas sold that company in 2002 and subsequently became in-house counsel focused on M&A matters and on security compliance issues surrounding HIPAA and SOX. Nicholas is a graduate of UCLA and Loyola Law School, Los Angeles, and is a member of the California Bar.

QB3 Webinar: Martin Babler, Former CEO, Principia Biopharma. "Building a Best-in-Class Platform for Immune-Mediated Disease"

Sanofi recently acquired Principia Biopharma for $3.7 billion. Principia, founded in 2008, built a portfolio of drugs to treat immune-mediated conditions including multiple sclerosis, pemphigus and immune thrombocytopenia purpura, all currently in Phase 3 trials. The portfolio was developed using Principia's Tailored Covalency® platform. Martin Babler, formerly Principia's CEO, joined the company when it started operations in 2011 and led it through several rounds of financing, the IPO and the acquisition. In this candid talk, Martin will relate hard-won lessons from his experience as CEO.
View Martin’s slide deck

Where & When

Zoom Webinar
Wednesday, December 9, 2:00 to 3:00 PM

About the Speaker

martin.jpg

Mr. Babler has served as Principia’s Chief Executive Officer since 2011 and as President and Chief Executive Officer since early 2019. From 2007 to 2011, Mr. Babler served as President and Chief Executive Officer of Talima Therapeutics. From 1998 to 2007, Mr. Babler held several positions at Genentech, most notably Vice President, Immunology Sales and Marketing. While at Genentech he also helped to build and led the Commercial Development organization and led the Cardiovascular Marketing organization. From 1991 to 1998, Mr. Babler was employed at Eli Lilly and Company in sales management, global marketing, and business development.

Mr. Babler presently serves on the Emerging Companies Section and Health Section Governing Boards of the Biotechnology Innovation Organization (BIO). Mr. Babler received a Swiss Federal Diploma in pharmacy from the Federal Institute of Technology in Zurich and completed the Executive Development Program at the Kellogg Graduate School of Management at Northwestern University.

QB3 Seminar: Pat Brown, Impossible Foods. "Mission Impossible: How I Launched and Scaled Up Impossible Foods"

The use of animals for food is one of the world's most destructive technologies. Convincing people to eat less animal meat can help solve the biggest issues facing us today, including the urgent threat of climate change, the collapse of biodiversity, and diet-related health issues. But meat is delicious. Is it possible to make cravable, nutritious meat at scale to feed our planet sustainably? In 2011, following an academic career at Stanford, biochemist Pat Brown launched Impossible Foods with a goal of eliminating animal agriculture by 2035. The company's first product, the award-winning Impossible Burger, includes the molecule heme, which Pat and his team initially tried harvesting from soy root nodules before inventing a method for mass manufacturing the ingredient. Now, Impossible Foods sells its products in more than 11,000 grocery stores and tens of thousands restaurants in the United States, Canada and key Asian markets, and the company is working on prototypes including milk, steak, fish and chicken. Join us to hear what Pat has learned about developing and scaling up foodtech to feed the world.

Where & When

Zoom Webinar
Friday, November 13, Noon to 1:00 PM

About the Speaker

IF_Pat_Brown.jpg

Patrick O. Brown is CEO and founder of Impossible Foods, a company at the forefront of making nutritious, delicious meat and dairy products from plants to satisfy meat lovers and address the environmental impact of animal farming.

The idea for Impossible Foods came to Pat while he was on sabbatical from his position as an HHMI investigator and professor of biochemistry at the Stanford University School of Medicine. In reflecting on how he could use his training and experience to make the largest positive impact on the world, he realized there was a way to make delicious, affordable meat and dairy products, directly from plants – that would be better for the environment and for consumers. In 2011, Pat chose to devote himself full time to Impossible Foods.

After receiving his BA, MD and PhD (in Biochemistry) at the University of Chicago, Pat completed a residency in pediatrics at Chicago’s Children’s Memorial Hospital. As a fellow with Mike Bishop and Harold Varmus, he defined the mechanism by which HIV and other retroviruses incorporate their genes into the genomes of the cells they infect.

At Stanford, Pat and colleagues developed DNA microarrays – a new technology that made it possible to monitor the activity of all the genes in a genome – along with the first methods for analyzing, visualizing and interpreting global gene expression programs.

He pioneered the use of gene expression patterns to classify cancers and improve prediction of their clinical course. He has also been a leader in making scientific and medical research results freely available to scientists, physicians and the public. With Harold Varmus, then Director of the National Institutes of Health, and Berkeley professor Michael Eisen, he founded the Public Library of Science, a nonprofit scientific publisher that has transformed the publishing industry by making scientific and medical research results freely available to the public.

He is a member of the National Academy of Sciences and the Institute of Medicine and recipient of the American Cancer Society Medal of Honor. He is also the co-founder of Lyrical Foods, Inc., maker of Kite Hill artisanal nut-milk-based cheeses and yogurts.


QB3 Seminar: Mickey Urdea, Halteres Associates. "A Commercial Backlash in COVID-19 Diagnostics? Historical Lessons Including Ebola"

The demand for rapid, accessible COVID-19 testing has driven more than a thousand companies to develop over 1800 diagnostic tests. Which solutions will meet commercial success depends on many factors including technology, use case, scalability, and of course cost. One or two years from now, which companies will stand strong, while their would-be competitors regroup or fail? Some predictions can be made, taking into account lessons learned from many historic diagnostic products and the 2014 Ebola outbreak. Join us on November 10 to learn more from Mickey Urdea, Founding Partner at Halteres Associates and a veteran in the field of development and commercialization of infectious disease diagnostics including the first viral load tests for HIV and HCV. View Dr. Urdea’s slide deck

Where and When

Zoom Webinar
Tuesday, November 10, Noon to 1:00 PM

About the Speaker

Urdea_Mickey.jpg

Dr. Urdea is Founder and Partner for Halteres Associates.

He also founded and served as Chief Executive Officer of Tethys Bioscience, a proteomics-based diagnostics company that has been involved in the prevention of type-2 diabetes (assets acquired by HDL), and was CEO of Quantum Dots Corporation (assets acquired by Life Technologies).

Additionally, Dr. Urdea is a founder and the Chairman of Catalysis Foundation for Health (CFH), a non-profit organization addressing gaps in global healthcare caused by inefficiencies in disease diagnosis and monitoring; CFH is developing potential biomarkers for tuberculosis bacterial load with a grant for the Bill & Melinda Gates Foundation.

Dr. Urdea is a member of the University of California at San Francisco Leadership Council for Global Health.

He serves as a consultant to the life sciences industry and is on the scientific advisory boards and boards of directors of a number of biotechnology and diagnostics companies.

Prior to his current activities, Dr. Urdea founded the Nucleic Acid Diagnostics business at Chiron Corporation, where he pioneered viral load assays for the human hepatitis B, hepatitis C and immunodeficiency viruses; his team introduced the first commercial viral load assays for all three viruses.

Dr. Urdea also headed the Oncology Diagnostics business unit at Chiron. He then became business head of the Molecular Diagnostics group and Chief Scientific Officer at Bayer Diagnostics. He has served as an advisor to the Bill & Melinda Gates Foundation for over ten years.

Dr. Urdea is an author on over 200 peer-reviewed scientific publications and has more than 125 issued and pending patents.

He received his BS in Biology and Chemistry from Northern Arizona University, his PhD in Biochemistry from Washington State University, and had an NIH postdoctoral fellowship at the University of California at San Francisco.

QB3 Seminar: Grey Frandsen, CEO, Oxitec. "Next-Gen Insect Control for Global Health"

The Florida Keys Mosquito Control District recently voted to move forward with a collaborative project for the release of Oxitec’s mosquitoes. The goal: to curb the spread of dengue and other diseases transmitted by the Aedes aegypti mosquito. The Oxitec mosquitoes are male and therefore non-biting, and carry a gene that prevents female offspring from surviving to maturity. UK-based Oxitec has additional technologies in development for public health and agriculture sustainability. Join this talk to hear from Oxitec CEO Grey Frandsen, who will discuss challenges and opportunities on this exciting frontier.

Where & When

Zoom Webinar
Tuesday, October 20, 2020, 9:00 to 10:00 AM PST (note early time; Mr. Frandsen is based in the UK)

About the Speaker

Grey Frandsen MVI_4863.jpg

Grey Frandsen was appointed the head of Oxitec’s global group in December, 2017. Prior to this role, Grey served in a number of executive and staff leadership roles in both the public and private sectors in the areas of national and public health security and in developing organizations devoted to solving large-scale public health threats globally.

Before and after September 11, 2001, Grey served in the U.S. Government in a range of leadership roles in conflicts and post-conflict stabilization operations around the world. Grey served in dozens of countries, primarily in Africa. Grey then served on the senior staff of two U.S Secretaries of State as the first Chief of Staff of the U.S. Government’s Office of Stabilization Operations. Grey also served as Senior Foreign Policy Advisor in the United States Senate with responsibility for national security and foreign and development policy oversight in areas of global public health, diplomacy, counter-terrorism, democracy and governance, and international development.

After government service, Grey served as the president of Olfactor Laboratories, Inc., a biotech startup developing a range of novel vector control technologies funded in part by the U.S. National institutes of Health (NIH) and venture funding (during which the NY Times called Grey a “mosquito mercenary”).

Grey served as an adjunct faculty member at the University of California San Francisco (UCSF) and a senior advisor to UCSF’s Global Health Group. In 2016, Grey co-founded a new public-private partnership in the British Virgin Islands to design and test a range of new public health initiatives and social technologies to combat the spread of vector-borne diseases. During the Zika crisis in the Western Hemisphere, Grey helped stand up the Puerto Rico Vector Control Unit and assisted the U.S. Centers for Disease Control Dengue Branch. In 2017, Grey developed a new policy and engagement framework for the Caribbean Regional Public Health Agency (CARPHA) designed to bolster government resiliency in combating vector-borne diseases.

Grey is currently the chair of the global board of directors for Pilgrim Africa, an NGO implementing innovative programs to combat malaria using novel combinations of mass drug administration, vector control and rapid diagnostics methods in some of Uganda’s most malaria-endemic regions. Grey served on faculty in the Department of Emergency and Military Medicine at the Uniformed Services University of Health Science (DOD) where he authored the military’s guide for, and trained military leadership in, civilian-military coordination in conflict and crises.

Grey received his BA at UCLA and an MA at the Johns Hopkins University School for Advanced International Studies (SAIS), where he was graduate student president and an Osgood Memorial Fellow. Grey was a Manfred Woerner Fellow with the German Marshall Fund and a fellow at the International Crisis Group in Brussels and Nairobi. In 2000, during his studies at UCLA, Grey co-founded his first company, PICnet, Inc., which is an American technology company that provides affordable web tools for non-profits, charities, NGOs, international organizations and advocacy organizations. PICnet, Inc. is celebrating 18 years this year having served more than 600 of the world’s leading social enterprises.

Grey and his work have been featured on CNN, BBC, Al Jazeera, MSNBC, NY Times, Washington Post, NPR, Financial Times, Forbes, Fast Co., Al Jazeera and dozens of other media outlets.

QB3 Seminar: Joe Lewcock, CSO, Denali Therapeutics. "Drug Discovery in Neurodegenerative Disease"

Denali Therapeutics develops therapeutics for neurodegenerative diseases such as Alzheimer's and Parkinson's. Three principles guide development: the target is genetically linked to the disease; the candidates are engineered for brain delivery; and clinical development is enabled by biomarkers. in this talk, Joe Lewcock, Chief Scientific Officer at Denali, will give an overview of the field and share progress that Denali has made toward urgently needed therapies.

Where & When

Zoom Webinar
Wednesday, October 7, 2020, 2:00 to 3:00 PM PST

About the Speaker

joe-lewcock.jpg

Joe serves as the Chief Scientific Officer at Denali.

In this role, he coordinates the discovery stage portfolio and activities ranging from new target discovery and validation to the identification of biomarkers to enable clinical trials. His group develops a range of therapeutic modalities to target aspects of neurodegeneration biology including Lysosomal Function, Glial Biology, Axon/Synapse maintenance, and the Blood-Brain Barrier.

Prior to joining Denali in early 2016, Joe spent 9 years at Genentech, where he helped to build the neuroscience research team and portfolio. In his role as Director of the Department of Neuroscience, he was responsible for generating the disease area strategy and management of the neuroscience portfolio, which included both large and small molecule programs. During his time at Genentech, Joe also served as a project team leader where he led a small molecule program for neurodegenerative disease from target discovery to IND filing and led a discovery lab focused on identification of new therapeutic drug targets for Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s Disease. He received his BS from University of California, San Diego, a Ph.D. from Johns Hopkins University School of Medicine, and did a Postdoctoral fellowship at the Salk Institute.

QB3 Seminar: Ryan Cirz. "How the Market Blocks Innovation in Antibiotics (And What You Can Do About It)"

Penicillin ranks as one of the greatest drugs of all time. But nearly 100 years after its discovery, antibiotic-resistant bacteria now pose a grave danger to public health. Who is developing new antibiotics to counter the threat? Very few companies, it turns out. Not because there is no need, but because of structural barriers in the market. Generics dominate, and big pharma has little interest in innovation or acquiring startups in the space. What's going on, and how might incentives be changed? Join us on Thursday, September 17 to hear from Ryan Cirz, founder and former VP of Research at Achaogen. Achaogen's Zemdri was once predicted to generate $500 million a year, but the company filed for bankruptcy in 2019. View Ryan’s slide deck

Where & When

Zoom Webinar
Thursday, September 17, 2020, 2:00 to 3:00 PM

About the Speaker

Ryan-Cirz_7x5-1.jpg

Ryan Cirz is an independent consultant. Previously, he was founder and Vice President of Research at Achaogen. Achaogen focused on discovering, developing and commercializing innovative antibacterials to treat multi-drug resistant (MDR) Gram-negative infections. Here, he participated in and led the advancement of four home-grown antibacterial assets through investigational new drug applications. Three of those programs advanced into the clinic with two advancing past phase one studies and one through US approval in 2018.

At Achaogen, he oversaw the early-stage (pre-investigational new drug) pipeline and provides intellectual insight/support to all things related to infectious diseases including late stage development, commercialization and medical affairs.

Ryan has a background in molecular biology and bacterial genetics, is passionate about medicinal chemistry in terms of scaffold design, lead optimization and selection and is well-versed in the broad scientific, policy and commercial challenges.

He has led the non-clinical portion of Achaogen and the Biomedical Advanced Research and Development Authority’s collaboration on plazomicin which required the design and execution of non-human primate efficacy studies on plazomicin for the treatment of Centers for Disease Control and Prevention (CDC) category A agents.

Ryan was a graduate researcher at the Scripps Research Institute in California, US. He was awarded his PhD in Biochemistry from The Scripps Research Institute and his BSc in biochemistry and molecular biology from Penn State University, Pennsylvania, US.

QB3 Seminar: Ray Deshaies, Amgen, & Kári Stefánsson, deCODE. "The Immunology and Genetics of Therapeutic Antibodies for SARS-CoV-2"

This April, Amgen started work on therapeutic antibodies targeting SARS-CoV-2. deCODE Genetics, an Amgen subsidiary in Iceland, is providing insights from patient samples on the genomics of the virus and individual patients. In this seminar, Kári Stefánsson, Founder & CEO of deCODE, will summarize what the company has learned about COVID-19. Ray Deshaies, Senior Vice President for Global Research at Amgen, will give us a look at how human “omics” data is providing insights into Amgen’s drug development projects.

Where & When

Thursday, August 20, 2020
Zoom Webinar

About the Speakers

Raymond Deshaies, Ph.D., Senior Vice President, Global Research, Amgen

RDeshaies Exec Photo 1.jpg

Raymond Deshaies, Ph.D., is senior vice president, Global Research, at Amgen.

Prior to joining Amgen, Deshaies served as a professor at the California Institute of Technology (Caltech) and an executive officer in Caltech’s Division of Biology and Biological Engineering. He was also an investigator at the Howard Hughes Medical Institute.

In addition to his academic work, Deshaies co-founded Proteolix in 2003. In 2011, he co-founded Cleave Biosciences.

Deshaies holds a bachelor's degree in biochemistry from Cornell University and a Ph.D. in biochemistry from the University of California, Berkeley. He is also a member of the National Academy of Sciences.

Kári Stefánsson, M.D., Dr. Med., Founder & CEO, deCODE genetics

kari-stefansson.png

Kári Stefánsson, M.D., Dr. Med., founded deCODE in August 1996. Dr. Stefánsson was previously a professor of Neurology, Neuropathology and Neuroscience at Harvard University and Director of Neuropathology at Beth Israel Hospital in Boston, Massachusetts. From 1983 to 1993, he held faculty positions in Neurology, Neuropathology and Neurosciences at the University of Chicago. Dr. Stefánsson received his M.D. and Dr. Med. from the University of Iceland and is board-certified in neurology and neuropathology in the United States. Dr. Stefansson is recognized as a leading figure in human genetics. He has shaped deCODE’s scientific approach and been actively engaged in leading its gene discovery work, serving as senior author on most of the company’s publications in major scientific journals.



QB3 Seminar: Trevor Martin, Mammoth Biosciences. "Mammoth Biosciences: A Different Approach to CRISPR"

This talk will be a Zoom webinar. Please register, and we will send you the link.

Mammoth Biosciences, a CRISPR startup spun out of UC Berkeley, is now at the leading edge of SARS-CoV-2 diagnostics, with a paper strip test in development. Mammoth's platform employs the DNA and RNA-cutting proteins Cas12 and Cas13 instead of the better-known Cas9. With a recent $45 million Series B round, Mammoth is doubling down on diagnostics while also expanding into gene editing and therapeutics. Join us on May 21 to hear from Mammoth's CEO and co-founder Trevor Martin.

Where & When

Zoom webinar
Thursday, May 21, 2:00 to 3:00 PM

About the Speaker

TrevorMartinTop 300.png

Dr. Trevor Martin, co-founder and CEO of Mammoth Biosciences, is leading the company on a mission to democratize access to the next generation of CRISPR tools for therapeutics and diagnostics. The Mammoth team, including fellow co-founder and CRISPR co-inventor Jennifer Doudna, has built the world’s broadest CRISPR platform and the world’s first CRISPR-based diagnostics platform capable of detecting any RNA or DNA biomarker. Trevor kicked off his career in science at Princeton as an undergraduate - in his time there, he conducted independent research in quantitative biology and was ultimately awarded the top honor for his senior thesis in molecular biology. After Princeton, Trevor went on to complete his Ph.D. in Biology at Stanford University with a NSF fellowship, combining techniques from statistics and genetics and developing methods around mapping the determinants of quantitative traits in both humans and microbes. In addition to having developed and taught multiple graduate level courses in statistics at Stanford, Trevor has penned educational guides for university courses across the globe. His work has been featured in outlets like FiveThirtyEight and The Atlantic, and he has been the featured healthcare honoree on Forbes’ 30 Under 30 list in 2018.

QB3 Seminar: George Scangos, Vir Biotechnology

Vir Biotechnology is at the forefront of the battle against infectious disease, including SARS-CoV-2. Join us on May 6 to hear about the latest developments at Vir from George Scangos, PhD, the company’s President and CEO, in conversation with QB3 Executive Director Reg Kelly, PhD, OBE.

Vir is developing platform technologies to stimulate and enhance the immune system. Dr. Scangos previously led Biogen, Exelixis, and Bayer Biotechnology, and has served on the boards of several publicly traded companies. We look forward to his insights and perspective.

Where & When

Zoom webinar
1:00 to 2:00 PM, Wednesday, May 6, 2020

This event was recorded. View it on YouTube

About the Speaker

GeorgeScangos.jpg

George Scangos, Ph.D., has served as Vir’s President and Chief Executive Officer and as a member of the board of directors since January 2017. From July 2010 to December 2016, Dr. Scangos served as Chief Executive Officer and as a member of the board of directors of Biogen Inc., a publicly traded biopharmaceutical company focused on the treatment of serious diseases. From October 1996 to July 2010, Dr. Scangos served as President and Chief Executive Officer at Exelixis, Inc., a drug discovery and development company. From 1993 to 1996, Dr. Scangos served as President of Bayer Biotechnology, where he was responsible for research, business development, process development, manufacturing, engineering and quality assurance of Bayer Biotechnology’s biological products. Before joining Bayer Biotechnology in 1987, Dr. Scangos was a Professor of Biology at Johns Hopkins University. Dr. Scangos has served as a member of the board of directors of various publicly traded companies, including: Exelixis, Inc., since 1996; Agilent Technologies, Inc., a life sciences, diagnostics and applied chemical analysis company, since 2014; and Anadys Pharmaceuticals, Inc., a biopharmaceutical company, from 2003 to 2010. Dr. Scangos served as Chair of PhRMA in 2016, and as the Chair of the California Healthcare Institute in 2010. He was a member of the board of directors of the Global Alliance for TB Drug Development from 2006 until 2010. Dr. Scangos currently serves on the Board of Trustees of Cornell University and the Board of Overseers of the University of California, San Francisco. Dr. Scangos received his B.A. in Biology from Cornell University and a Ph.D. in Microbiology from the University of Massachusetts.

QB3 Seminar: Sean George, Invitae. "Acquisition as Growth Strategy in the Diagnostics Space"

Many founders hope to grow their startup to the point that it is acquired by a larger company. But startups can grow by acquiring other companies and technologies themselves. How does acquisition give you a stronger position in the market? Join us on Thursday, April 16 to learn from Sean George, CEO of Invitae, a genetic information company which has made 10 acquisitions since 2017.

georgesean012518tj-2*1200xx6234-3507-0-327.jpg

About the Speaker

Sean is chief executive officer of Invitae, whose mission is to bring genetic information into mainstream medicine. Prior to his CEO position, he served as Invitae’s president and chief operating officer. Sean was a co-founder and CEO of Locus Development, an early stage genetic analysis startup that later merged with Invitae. Prior to co-founding Locus, he served as COO at Navigenics, an early leader in personalized medicine. Previously, he has also served as SVP of Marketing and SVP, Life Science Business at Affymetrix as well as VP, Labeling and Detection Business at Invitrogen. In the past, he has also worked at McKinsey & Co. and Molecular Probes. Dr. George holds a B.S. in Molecular Genetics from UCLA, an M.S. in Molecular Biology from UC Santa Barbara, and a Ph.D. in Molecular Genetics from UC Santa Cruz.

*CANCELED* Rosenman D-Series: Aaron Sandoski, Norwich Ventures. "What Is Success in Healthtech Convergence?"

Unfortunately, due to COVID-19 concerns, Norwich Ventures has instated a company travel ban. Attendees with paid tickets will be refunded. Aaron is unable to travel to San Francisco for this talk. He expects to be able to make it in the fall, and we look forward to seeing you then.

Startup founders whose technologies embody the convergence of AI, data, or telehealth with traditional engineering must develop wide-ranging business models. It is no longer enough to focus on a product by itself; founders must take a systems approach and consider all stakeholders that interact with the data or technology. Aaron Sandoski, co-founder & managing director of Norwich Ventures, will explain how his investment firm assesses early-stage companies with convergent technologies.

Where & When

Room N-114, Genentech Hall, UCSF Mission Bay (600 16th St., San Francisco)
Tuesday, March 10, 2020, 5:30 to 6:30 PM

About the Speaker

sandoski 200.png

Aaron Sandoski is Co-Founder & Managing Director of Norwich Ventures, a specialized venture capital firm focused on early-stage MedTech.  Aaron’s current investments include Affera, Arterys, Lexington Medical, Pelvalon, Podimetrics, ReThink Medical and Vaxess Technologies.  Previous investments include Rhythmia Medical (acquired by Boston Scientific) and Intelligent Bio-systems (acquired by Qiagen).  Prior to founding Norwich Ventures, Aaron worked for DEKA R&D, the engineering think tank of Dean Kamen.  He has also worked in start-up operations where he helped launch a subsidiary of Express Scripts and helped launch a venture-backed payments company. Aaron began his career as a consultant at McKinsey & Company, where he advised healthcare clients ranging from leading medical device companies to a rural hospital system.  Aaron is co-author of How the Wise Decide (Crown Business), a book on best practices in making tough decisions, which has been translated into 11 foreign languages.  Aaron earned an MBA from Harvard Business School and graduated summa cum laude from Dartmouth College with a double A.B. in Chemistry and Economics.

Rosenman D-Series: Sam Williams, Brown Rudnick. "How to Prepare to Sell Your Life Science or Medtech Company"

To ensure a successful sale of your startup you need to start planning early. Several issues are key. Among them: how to maximize value; how to manage stakeholders; and how to close the deal, which is everything once you decide to sell. To learn how to do it right—as well as hard-learned lessons about what happens if you don't—join us on Thursday, February 20 to hear from Sam Williams, a partner in corporate law at the firm Brown Rudnick.

Where & When

Room 212, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)
5:30 to 6:30 PM, Thursday, February 20, 2020

About the Speaker

Williams_Sam_WEB.jpg

Sam Williams concentrates his practice on corporate finance, mergers and acquisitions, venture capital, licensing and strategic partnerships and international law. He counsels publicly and privately held corporations in a variety of industries including businesses in the information technology, semiconductor, communications and other high technology sectors.

In addition to his transactional experience, Sam has considerable experience guiding clients in formulating their intellectual property, licensing and distribution arrangements and in establishing domestic and multinational strategic partnerships. He advises clients in complying with securities laws in proxy solicitations, the ongoing reporting requirements of public companies, antitakeover techniques and a broad range of other matters affecting companies and their officers and directors.

As part of Brown Rudnick’s Family Office team, Sam is also part of collaborative, cross-disciplinary initiatives assisting clients in this area.

Sam is consistently recognized in Chambers USA: America’s Leading Lawyers for Business as well as being recognized by his peers for inclusion in The Best Lawyers in America© in the field of Corporate Law.

QB3 Seminar: Anna Christensen, CEO & Co-Founder, Magnetic Insight. "Disrupting the Magnetic Imaging Market"

Magnetic Insight is an Alameda-based, early stage company that has commercialized a disruptive new medical imaging platform complementing CT, MRI and PET workflows with magnetic particle imaging, a precise and sensitive new imaging modality for vascular imaging, inflammation staging and cell therapy monitoring. Last July the company moved into a 22,000 square foot facility where they have set up a state of the art operation to develop and manufacture a line of products that now ship worldwide. Join us on Tuesday, February 11, to hear from Anna Christensen, who will relate the lessons she has learned as the company’s co-founder and CEO.

Where & When

Room 212, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)
Noon to 1:00 PM, Tuesday, February 11

This is a brown bag event.

About the Speaker

Incubator-Magnetic-Insight-CEO-2.jpg

Dr. Anna Christensen is the CEO and co-founder of Magnetic Insight. She has spent the last 16 years commercializing platform technologies in imaging and diagnostics. Most recently, she led the in vivo imaging business for PerkinElmer Inc and Caliper Life Sciences as the global business leader. Prior to Caliper Life Sciences, she held senior management positions at DiscoverX and Molecular Devices. In addition to her commercial experience, she holds advanced degrees in cell biology and neurobiology from UC San Diego and Copenhagen University.

Rosenman D-Series: Tak Cheung, NEA. “VC Healthtech Investing at NEA”

Where & When

Room 212, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)
5:30 to 6:30 PM, Thursday, December 5, 2019

About the Speaker

NEA_Tak Cheung_headshot.jpg

Tak joined NEA in 2018 as a Principal on the healthcare team. He focuses on medical device investments.

Prior to NEA, Tak was a Venture Partner at Merieux Development Venture Fund where he led all phases of investment for healthcare startups, including sourcing, diligence and investment approvals. Tak also co-founded Lexington Medical, a commercial-stage medical device startup in the gastrointestinal surgery space. Prior to Merieux and Lexington, Tak was VP of Business Development for the Global Surgical Division at Bausch & Lomb, and was responsible for all business development efforts in the ophthalmic surgical division. Tak has held various corporate and business development leadership roles at Edwards Lifesciences in the Heart Valve Therapy Division and Advanced Medical Optics (acquired by Johnson & Johnson).

Tak received a BS with Honors in Engineering and Applied Science from the California Institute of Technology, an MD from the University of California, Irvine, and an MBA from Harvard Business School.